Hamdi L. Doganay

Bahcesehir, TR 
Bahcesehir, TR 

Overview

Hamdi Doganay practices practicing medicine in Bahcesehir, Turkey.

Their clinical expertise encompasses Erysipelas, Hepatitis B, Severe Acute Respiratory Syndrome (SARS), and Familial Mediterranean Fever.

They are actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 2 clinical trials.

Locations

Bahcesehir, Turkey
Other Locations
Istanbul, Turkey
Umraniye, Turkey
Uemraniye, Turkey
Haydarpasa, Turkey

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial For Evaluation of Efficacy and Safety of SARS-CoV-2 Vaccine (Vero Cell), Inactivated
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drug: CoronaVac Vaccine
Study Phase: Phase 3
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial
Efficacy, Immunogenicity, and Safety of the Two-Dose Inactivated COVID-19 Vaccine (TURKOVAC) Versus the Two-Dose CoronaVac (Sinovac) Vaccine in Healthy Subjects: A Randomized, Observer-Blinded, Phase III Clinical Trial
Enrollment Status: Completed
Publish Date: February 29, 2024
Intervention Type: Biological
Study Phase: Phase 3
View 1 Less Clinical Trial

29 Total Publications

Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients.
Variant reclassification in cancer susceptibility genes and an updated variant spectrum of Turkish breast and colorectal cancer patients.
Journal: Human genomics
Published: October 17, 2025

Frequently Asked Questions about Hamdi L. Doganay

Is Hamdi L. Doganay a top-rated expert for Erysipelas?

MediFind is an objective health platform that identifies experts based on real-world data. Hamdi L. Doganay is classified as an Experienced expert for Erysipelas, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Hamdi L. Doganay participate in research or clinical trials?

Yes. Hamdi L. Doganay has published 29 articles and abstracts on conditions like Erysipelas. You can view a list of Hamdi L. Doganay's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Doganay's expertise for a condition
ConditionClose
        View All 15 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile